AI-Written Hospital Discharge Summaries and the Challenge of Verification
-
By
-
Melanie F. Molina
-
November 17, 2026
By
Melanie F. Molina
November 17, 2026
Approved for metastatic and early-stage breast cancer, the biosimilar cannot launch in the US before Q3 2028.
by Mouj Hijazi
November 17, 2026
Sustained remission reached 40.5% with secukinumab vs 20.5% with placebo at 52 weeks, alongside lower steroid exposure.
by Mouj Hijazi
November 17, 2026
Researchers found substantial weight reduction alongside improvements in osteoarthritis pain and sleep apnea severity in a phase 3 trial.
November 11, 2026